Literature DB >> 15962176

Recombinant viruses as vaccines against viral diseases.

A P D Souza1, L Haut, A Reyes-Sandoval, A R Pinto.   

Abstract

Vaccine approaches to infectious diseases are widely applied and appreciated. Amongst them, vectors based on recombinant viruses have shown great promise and play an important role in the development of new vaccines. Many viruses have been investigated for their ability to express proteins from foreign pathogens and induce specific immunological responses against these antigens in vivo. Generally, gene-based vaccines can stimulate potent humoral and cellular immune responses and viral vectors might be an effective strategy for both the delivery of antigen-encoding genes and the facilitation and enhancement of antigen presentation. In order to be utilized as a vaccine carrier, the ideal viral vector should be safe and enable efficient presentation of required pathogen-specific antigens to the immune system. It should also exhibit low intrinsic immunogenicity to allow for its re-administration in order to boost relevant specific immune responses. Furthermore, the vector system must meet criteria that enable its production on a large-scale basis. Several viral vaccine vectors have thus emerged to date, all of them having relative advantages and limits depending on the proposed application, and thus far none of them have proven to be ideal vaccine carriers. In this review we describe the potential, as well as some of the foreseeable obstacles associated with viral vaccine vectors and their use in preventive medicine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962176     DOI: 10.1590/s0100-879x2005000400004

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  23 in total

1.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Novel antigen delivery systems.

Authors:  Maria Trovato; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2015-08-12

3.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

Review 4.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

5.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

6.  Construction and immune response characterization of a recombinant pseudorabies virus co-expressing capsid precursor protein (P1) and a multiepitope peptide of foot-and-mouth disease virus in swine.

Authors:  Yannan He; Ping Qian; Keshan Zhang; Qingxia Yao; Dang Wang; Zhuofei Xu; Bin Wu; Meilin Jin; Shaobo Xiao; Huanchun Chen
Journal:  Virus Genes       Date:  2008-02-02       Impact factor: 2.332

Review 7.  Novel viral vectored vaccines for the prevention of influenza.

Authors:  Teresa Lambe
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

8.  Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.

Authors:  Miriam Nörder; Pablo D Becker; Ingo Drexler; Claudia Link; Volker Erfle; Carlos A Guzmán
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

9.  TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 10.  An overview of live attenuated recombinant pseudorabies viruses for use as novel vaccines.

Authors:  Bo Dong; Dante S Zarlenga; Xiaofeng Ren
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.